Ann: Orthocell Board Change, page-7

Hey Merry Xmas guys and gals. Hope you all stay safe and healthy over the break.

Appreciate everyone's input and dissenting points of view too.

As Bedger pointed out above, the R&D is largely responsible for our expenditure and that's set to continue in the next calendar year as well, which means some continued pressure to the share price as certain brokers/retail refuse to differentiate the various expenses.

I know of an investor that closed recently sighting continued high expenditure and lack of communication from Mgt as key reasons.

Hopefully receipts come in strong this next quarter and we have another record quarterly to celebrate. Sadly it's the only way this company is ever going to get traction. The good news is I that the chart has been consolidating here and is trying to push up against some residual pressure with a few shorts doing their level best to take advantage of the lack of buying over the break.

Merry Xmas and a safe New Year to you all.